Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: JAKAFI

« Back to Dashboard
Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

This drug has forty-four patent family members in twenty-seven countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

Summary for Tradename: JAKAFI

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: JAKAFI

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: JAKAFI

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Status: Recruiting Condition: Leukemia; Myeloproliferative Diseases

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Status: Recruiting Condition: Myeloproliferative Diseases

Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Status: Recruiting Condition: Leukemia

Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Status: Not yet recruiting Condition: Leukemia

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib in Colorectal Cancer Patients
Status: Recruiting Condition: Metastatic Colorectal Cancer

Phase l/II Study of Ruxolitinib for Acute Leukemia
Status: Active, not recruiting Condition: Leukemia

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Status: Recruiting Condition: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis

A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Status: Completed Condition: Plaque Psoriasis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET; ORAL202192-004Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET; ORAL202192-004Nov 16, 2011RXNo7,598,257<disabled>YY<disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET; ORAL202192-002Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET; ORAL202192-001Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
JAKAFI
ruxolitinib phosphate
TABLET; ORAL202192-003Nov 16, 2011RXNo7,598,257<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JAKAFI

Country Document Number Publication Date
Australia2006326548Jun 21, 2007
Costa Rica10065Jul 10, 2008
CroatiaP20110903Jan 31, 2012
Israel192019Dec 29, 2008
Portugal1966202Jan 03, 2012
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc